Prakash Industries Regulatory Approval

Board Meeting Date

Prakash Industries Board Meeting Date

Prakash Industries Ltd intimated a board meeting on 12 November 2026 to consider unaudited results for the quarter and half year ended 30 September 2026. The trading window stays closed until 48 hours after the results are made public.

Other Announcement

Prakash Industries Other Announcement

Prakash Industries Ltd has filed its quarterly shareholding pattern for the quarter ended September 30, 2026, in compliance with SEBI regulatory requirements.

Annual General Meeting

Prakash Industries Annual General Meeting

Prakash Industries Limited conducted its 45th Annual General Meeting on 30th September 2026. The meeting covered financial statements, dividend approval, and auditor appointments.

Business Update

Prakash Industries Business Update

Prakash Industries has received Consent to Operate from CECB to expand its Bhaskarpara Coal Mine production capacity from 1.0 MTPA to 1.2 MTPA.

coal mine production capacity expansion

0.2 MTPA

Other Announcement

Prakash Industries Other Announcement

Prakash Industries has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This filing is a regulatory compliance requirement.

Annual Report

Prakash Industries Annual Report

Prakash Industries Limited has submitted its Annual Report for the financial year 2025-26, complying with Regulation 34 of SEBI (LODR) Regulations, 2015.

Regulatory ApprovalWanbury Ltd WANBURYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Wanbury Regulatory Approval

Wanbury received ANVISA (Brazil FDA) CADIFA approval for Metformin HCl EP grade API, its third consecutive ANVISA clearance. The company has initiated customer talks to increase API volumes in Brazil.

Regulatory ApprovalSandur Manganese & Iron Ores Ltd SANDUMAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Sandur Manganese & Iron Ores Regulatory Approval

Sandur Manganese received environmental clearance to raise iron ore capacity to 9.42 MTPA. No rupee value is disclosed in the filing.

iron ore RoM capacity

9.42 MTPA

Regulatory ApprovalNeogen Chemicals Ltd NEOGENAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Neogen Chemicals Regulatory Approval

Neogen Chemicals received GPCB's revocation of its Dahej plant direction and a CC&A amendment for manufacturing. The revocation is for three months with conditions attached.

Regulatory ApprovalArihant Capital Markets Ltd ARIHANTCAPAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Arihant Capital Markets Regulatory Approval

Arihant Capital Markets received SEBI in-principle approval to sponsor and set up a mutual fund. Final registration remains subject to SEBI's conditions.

Regulatory ApprovalDr. Reddy's Laboratories Ltd DRREDDYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Dr. Reddy's Laboratories Regulatory Approval

Dr. Reddy's Laboratories received marketing authorization from Brazil's ANVISA for its generic semaglutide injection. The approval targets Brazil's diabetes market, estimated at approximately USD 244.6 million.

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for its generic Olopatadine Hydrochloride Ophthalmic Solution 0.7% ANDA. The product's US market is estimated at $20 million, per IQVIA.